There is increasing evidence that phenylacetate inhibits growth and modulates differentiation in a variety of tumors with effects on gene expression, and protein prenylation and glycosylation at concentrations that have been safely used in humans. We evaluated the antineoplastic effects of phenylacetate in five thyroid cancer cell lines of follicular cell origin in vitro. We found early growth inhibition occurred with phenylacetate treatment at a dose of 2.5-10 mmol/L. The growth inhibition was cytostatic with the thyroid carcinoma cells arrested in the G 0 -1 cell phase. When evaluating the effect of phenylacetate on the differentiated functions of thyroid carcinoma cells, phenylacetate exposure: 1) decreased the TSH (10 mU/mL) growth response; 2) increased radioactive iodine ( 125 I) uptake in two out of five cell lines; and 3) inhibited thyroglobulin secretion. Phenylacetate also inhibited the secretion of vascular endothelial growth factor (a glycoprotein dependent on glycosylation for efficient cellular excretion) from the thyroid cancer cell lines. Our results support that phenylacetate has an antiproliferative effect in many cell types, but the differentiating effects were not uniform. Importantly, we have identified that phenylacetate inhibits the secretion of vascular endothelial growth factor, which possibly mediates the antiangiogenic effects observed in vivo. Because of the minimal toxicity associated with phenylacetate treatment in humans, at concentrations we show to have a significant antineoplastic effect in thyroid carcinoma cells, phenylacetate could be useful in patients with differentiated thyroid cancer who fail conventional therapy or as an adjuvant to radioactive iodine therapy in patients with aggressive tumors. (J Clin Endocrinol
also inhibited the secretion of vascular endothelial growth factor (a glycoprotein dependent on glycosylation for efficient cellular excretion) from the thyroid cancer cell lines. Our results support that phenylacetate has an antiproliferative effect in many cell types, but the differentiating effects were not uniform. Importantly, we have identified that phenylacetate inhibits the secretion of vascular endothelial growth factor, which possibly mediates the antiangiogenic effects observed in vivo. Because of the minimal toxicity associated with phenylacetate treatment in humans, at concentrations we show to have a significant antineoplastic effect in thyroid carcinoma cells, phenylacetate could be useful in patients with differentiated thyroid cancer who fail conventional therapy or as an adjuvant to radioactive iodine therapy in patients with aggressive tumors. (J Clin Endocrinol Metab 84: 2840 -2847, 1999) T HYROID CANCER is the most common endocrine malignancy and has the highest mortality among endocrine neoplasms, excluding ovarian cancer (1) . Although most patients with thyroid cancer of follicular cell origin do well when the tumor is resectable or is ablated with radioactive iodine therapy, patients with distant metastases, extrathyroidal invasion, high-grade tumors, or who are older have a high risk of recurrence (ϳ30%) and mortality (ϳ40%) (2, 3) . Cytotoxic drugs and external radiation have been, at best, palliative in patients with thyroid cancer (3) .
Cellular dedifferentiation is a common event in malignant transformation and/or progression, and it occurs in up to one-third of differentiated thyroid cancers (DTC) (4) . About 1% of DTCs transform into anaplastic thyroid cancer, which is almost uniformly lethal (5) . In DTC, iodine uptake and metabolism, TSH receptor expression, thyroglobulin synthesis and secretion, and thyroid peroxidase activity are markers of thyrocyte differentiation (6 -8) . Patients with DTCs that have decreased or no radioactive iodine uptake often have more aggressive tumors and are difficult to treat. Several antiproliferative and differentiating agents (such as tamoxifen, retinoic acid, and Octreotide) have been evaluated in thyroid cancer experimental models leading to clinical evaluation in patients who did not benefit from conventional therapy (9 -13) .
Phenylacetate (an aromatic fatty acid) has been reported to have a potent antiproliferative and differentiating effect in hematologic malignancies and multiple solid tumors at nontoxic concentrations (14) . It is present in low concentration (2-4 mol/L) in human serum as a product of phenylalanine metabolism and is conjugated with glutamine in the liver by phenylacetyl coenzyme A to form phenylacetylglutamine (15) . Based on this, it has been used safely to treat children with inborn errors of urea synthesis and also in patients with hyperammonemia (16 -18) . In patients with hormone refractory prostate cancer and high-grade glioma, phase I trials of phenylacetate showed minimal toxicity; and a partial response was observed at a serum concentration of 2-10 mmol/L (19, 20) . Increasing evidence points to phenylacetate having multiple effects on gene expression and regulatory proteins responsible for its antineoplastic effects. In this study, we evaluated the antiproliferative and differentiating effect of phenylacetate in well-characterized human thyroid cancer cell lines of follicular cell origin.
Materials and Methods Materials
The following reagents and materials were used: DMEM:F12 media, l-glutamine, 1ϫ Trypsin/EDTA solution, 1ϫ PBS from Cellgro Medi- 
Cell lines and culture conditions
All three follicular thyroid cancer (FTC) cell lines were established from a single patient and were kindly provided by Dr. Peter Goretzki (Germany). FTC-133 was derived from a primary thyroid tumor, FTC-236 from a lymph node metastasis, and FTC-238 from a lung metastasis (21) . A papillary thyroid cancer cell line (TPC-1) was kindly provided by Dr. Nabuo Satoh (Japan), and the Hü rthle cell carcinoma cell line (XTC-UC1) was established in our laboratory from a metastasis to the breast (22) .
The cell lines were maintained in DME:12 supplemented with 10% FBS, penicillin (10,000 U/mL), streptomycin (10,000 U/mL), fungizone (250 mg/mL), TSH (10 mU/mL), glutamine (12.5 mg/L), and insulin (5 mg/mL) in a standard humidified incubator at 37 C in a 5% CO 2 -95% O 2 atmosphere. All experiments were performed in a serum-free environment using DME:12 media supplemented with four hormones (H5); transferrin (5 g/mL), SRIF (10 ng/mL), glycl-l-histidyl acetate (2 ng/ mL), and hydrocortisone (0.36 ng/mL), a modified Ambesi-Impiombato method (23) . The culture media were changed to H5 media, 48 h before conducting experiments.
Thyroid tissue culture
Fresh normal thyroid tissues adjacent to thyroid neoplasms were obtained immediately upon surgical removal and maintained on ice. All experiments and tissue procurement were approved by the Committee on Human Research at the University of California, San Francisco. The tissues were cut into 1-to 5-mm pieces in 1ϫ PBS, then pelleted and treated with collagenase for 45 min and 1ϫ trypsin/EDTA solution for 15 min. The digested solution was pelleted, resuspended in maintenance media, and incubated in a 125-cm 2 flask in a humidified incubator. Geneticin (10 ng/mL) was used to eliminate fibroblast growth, if present, in the thyroid monolayer cultures. Primary culture thyroid cells were harvested at a 100% confluency to confirm the accuracy of 125 Iuptake assay studies.
Proliferation assay
Growth experiments were done in a 96-well plate in triplicate. Cells at 100% confluency were harvested with 1ϫ Trypsin/EDTA solution and seeded into a 96-well plate at 5 ϫ 10 3 cells per well and maintained in 200 L H5 medium in a humidified incubator. Phenylacetate salt was reconstituted in H5 media, to a pH of 7.4, using NaOH. After 24 h, the cells were incubated with 0, 2.5, 5.0, 7.5, 10, and 50 mmol/L phenylacetate with the media changed daily. Colorometric MTT (dimethylthiazol-diphenyltetrazolium bromide) proliferation assays were performed at 0, 24, 48, 72, and 96 h. MTT (400 g/mL) was added to each well and incubated for 3 h. It was solubilized with 0.04 N HCL/Isopropanol/3% SDS and incubated for 1 h. The optical densities in the 96-well plates were determined using an ELISA microplate reader (Molecular Devices) at 595 nm/620 nm (1-reference).
Flow cytometry analysis
The thyroid cancer cell lines (FTC-236, TPC-1, and XTC-UC1) were incubated, with and without phenylacetate (10 mmol/L) for 24 h, to assess the effect of phenylacetate on cell cycle progression. Subconfluent cells were harvested, pelleted, alcohol fixed, and resuspended in 1ϫ PBS to a concentration of 1 ϫ 10 6 cells/mL. To eliminate staining artifacts from double-stranded RNA binding propidium iodide, ribonuclease (deoxyribonuclease-free @ 100 g/mL) was added to each cell suspension and incubated for 1 h at 4 C.
Flow cytometric analysis was performed on a Becton Dickinson and Co. FACScan. Data files were generated for 20,000 events (cells) or more per sample using the CELLQuest software. The ModFit LT cell cycle analysis software from Verity Software House, Inc. was used to analyze the data files.
TSH growth response
The cells were maintained in H5 medium, with phenylacetate treatment (10 mmol/L) or without (control), for 72 h, then harvested and seeded into a 96-well plate at 1 ϫ 10 4 cells/well in 200 L H5 medium with 10 mU/mL TSH. As described earlier, proliferation MTT assays were performed 24 h after TSH stimulation.
Iodine-uptake studies
Cells were maintained in H5 media, with (7.5 mmol/L) and without phenylacetate, for 72 h, then harvested using a cell scraper, and pelleted. The total cell number of each sample was determined by hemocytometry, and 2 ϫ 10 6 cells were resuspended in HBSS with 0.5 mmol/L sodium iodine and 2 Ci of 125 I for an activity of 20 mCi/mmol. The solution was then incubated at 37 C for 2 h, then pelleted, and washed with 1 mL ice-cold HBSS three times.
To determine the 125 I associated with the cells, the pellet was resuspended in 1 mL 95% alcohol and incubated for 20 min at room temperature. Triplicates (200 L) of each sample were immediately counted in a ␤ counter (COBRA Auto-gamma) for 5 min. Blank background samples (without cells) showed less than 5.5% of sample radioactivity. The 125 I uptake in the cell lines, using 10% trichloroacetic acid instead of alcohol, gave similar results. Before sample incubation with 125 I and uptake measurement, the cell viability was greater than 96%, by trypan blue dye exclusion. The 125 I uptake is reported as cpm/100,000 cells.
Thyroglobulin measurement
To assess the effect of phenylacetate on thyroglobulin synthesis and secretion in the thyroid cancer cell lines, each cell line (2 ϫ 10 6 cells) was maintained in H5 media, with (10 mmol/L) and without phenylacetate, in a 25-cm 2 flask. To determine thyroglobulin secretion, the culture media was collected at 12, 24, and 48 h; and the thyroglobulin levels were measured commercially (Quest Diagnostics, Inc., Nicholas Institute, Clinical Studies Center, San Juan Capistrano, CA). To measure the effect of phenylacetate on thyroglobulin synthesis, the intracellular thyroglobulin levels, after incubation with and without phenylacetate (10 mmol/L) at 12, 24 and 48 h, were determined after protein lysate preparation. The cells were harvested, pelleted, and washed with 1 mL of 1ϫ PBS and homogenized in 1ϫ PBS/1% IGEPAL CA-630/0.5% SDS for 1 h. The protein concentration of the lysates was quantified using the BioRad Laboratories, Inc. protein assay (based on the Bradford method), as described by the manufacturer. The protein lysate samples were diluted 1:10 in H5 media, and the thyroglobulin levels were measured.
VEGF ELISA
VEGF secretion in the thyroid cancer cell lines was measured in 96-well plates (5 ϫ 10 3 cells/well) triplicates maintained in 250 L H5 media after 12 h incubation with and without phenylacetate (10 mmol/ L). The medium from each well was collected to determine VEGF secretion. VEGF ELISAs were done using the Quantikine immunoassay kit, as described in the manufacturer's protocol. The optical density in the 96-well plates was determined using an ELISA microplate reader at 450 nm/595 nm (1-reference). Protein lysates were prepared and quantified as described above under the same culture conditions. To measure the intracellular VEGF level, the VEGF ELISA system was also used after a 1:4 dilution of the protein lysate samples.
RNA extraction and Northern blot analysis
Total RNA was extracted by the single-step acid guanidium thiocyanate-phenol-chloroform method using the RNAzol solution. Ten micrograms of total RNA was electrophorized on a 1.2% agarose/1.9% formaldehyde gel, transferred onto a nylon membrane, and cross-linked by ultraviolet irradiation. VEGF complementary DNA (cDNA) probes (160-bp fragment) were excised from 2.1 kb Bluescript II KS plasmid with ClaI and SstI, and ␤-actin cDNA probes (1.1-kb fragment) from a Bluescript SK plasmid with EcoRI. The probes were radiolabeled with [ 32 P] deoxycycidine triphosphate by random priming. The nylon membranes were prehybridized at 65 C and hybridized at 65 C with labeled cDNA probes. The membranes were washed to a stringency of 0.1% SSPE and 0.1% SDS at 65 C and exposed to Kodak XAR-5 x-ray films for 24 -48 h at Ϫ80 C. The resulting autoradiograph band intensities were quantified using an autoradiography densitometry imaging analyzer. The VEGF messenger RNA (mRNA) signals were normalized to the ␤-actin mRNA signals in the same lanes to control for RNA loading and transfer. For rehybridization, the membranes were stripped for 10 min at 100 C using a 0.05% XSSPE, 0.1% SDS, and 20 mmol/L EDTA solution.
Statistical analysis
The student's t test for paired data and ANOVA for multiple group (control plus multiple phenylacetate treatment concentration) comparison were used with a statistically significant result defined as P Ͻ 0.05.
Results

Antiproliferative effects of phenylacetate in human thyroid carcinoma cell lines
We found growth inhibition, with phenylacetate treatment, in all the thyroid cancer cell lines studied at nontoxic concentrations (2.5-10 mmol/L). The antiproliferative effect of phenylacetate was time-and dose-dependent in all the cell lines (Fig. 1, A and B) . The antiproliferative effect of phenylacetate does not seem to be a cytotoxic effect, because the cell viability was greater than 96% with exposure to 10 mmol/L of phenylacetate. Growth inhibition, with phenylacetate (10 mmol/L), occurred as early as 24 h after exposure in all the cell lines ranging, from 12-37% (P Ͻ 0.05). FACS analysis of subconfluent cell lines (FTC-236, TPC-1, and XTC-UC1) exposed to phenylacetate, compared with unexposed (control) cell lines, showed a decrease (5-14%, P Յ 0.03) in the percent of S-phase cells, with a corresponding increase (2-7%, P Յ 0.03) in the percent of G 0 -1 -phase cells. It has been shown that phenylacetate can bind glutamine and deplete serum circulating levels in humans. Because we used a glutamine-free culture experimental model, we also conducted experiments to see whether the presence of glutamine reversed the antiproliferative effect of phenylacetate observed. Glutamine supplementation of two times the physiologic level did not reverse the antiproliferative effect of phenylacetate (data not shown). Morphologic changes in the thyrocyte monolayer culture system occurred late with phenylacetate treatment and consisted of cell detachment from the flask, rounded-up cells, and decreased cellular cytoplasm with prominent nuclei formation (Fig. 2) .
Phenylacetate effect on the differentiated function of thyroid carcinoma cells
Our previous studies show that all the thyroid cancer cell lines have increased growth with TSH (10 mU/mL) stimulation (22, 24) . Therefore, we were interested in determining whether phenylacetate exposure could potentiate this response (i.e. have a redifferentiating effect). Phenylacetate treatment decreased the growth response to TSH stimulation, compared with unexposed cell lines (Fig. 3) . This suggests a primarily antiproliferative effect of phenylacetate in the thyroid cancer cell lines evaluated. Phenylacetate treatment in the TPC-1 and XTC-UC1 cell lines increased 125 I uptake by 82% and 108%, respectively, compared with unexposed cell lines (Table 1 ). This effect was not observed in the more invasive FTC cell lines (FTC-133, FTC-236, and FTC-238) (24) . Only the XTC-UC1 cell line had an appreciable thyroglobulin level secreted in the condition media collected. When exposed to phenylacetate, we found a time-dependent inhibition of thyroglobulin secretion 20% (8 h) and 69% (24 h) (P Ͻ 0.05). To differentiate whether this was an effect on the secretion or synthesis of thyroglobulin, we determined the intracellular thyroglobulin levels. Phenylacetate treatment in the XTC-UC1 cell line had no effect up to 24 h; but by 48 h, there was an increased intracellular thyroglobulin level, compared with control (250% increase, P ϭ 0.03). This suggests that phenylacetate inhibits the secretion of thyroglobulin, causing intracellular accumulation.
Phenylacetate inhibits VEGF secretion, but not VEGF synthesis or expression, in human thyroid cancer cell lines
Because of our finding that phenylacetate inhibited secretion of thyroglobulin (a glycoprotein like VEGF) and another report that suggests that phenylacetate may inhibit angiogenesis, we reasoned that phenylacetate might also inhibit the secretion of VEGF (a glycoprotein known to be dependent on N-linked glycosylation for efficient secretion) (25) . Phenylacetate inhibited the secretion of VEGF, in all the cell lines, 38 -68% at 12 h [P Ͻ 0.05 for all the cell lines, except TPC-1 (P ϭ 0.06)]. We performed Northern blot analysis to determine whether phenylacetate exposure might have decreased VEGF secretion by down-regulating VEGF mRNA expression, but we found no difference between exposed and unexposed cell lines (Fig. 4) . Phenylacetate treatment did increase intracellular VEGF levels in the TPC-1 and XTC-UC1 cell lines (78% and 70%, respectively, compared with untreated cell lines at 12 h, P Ͻ 0.05). This also suggests that phenylacetate inhibits the efficient secretion of VEGF in human thyroid carcinoma cells.
Discussion
The rationale for evaluating the antineoplastic effects of phenylacetate in differentiated thyroid carcinoma cells is that patients with invasive and metastatic tumors are difficult to treat (26) . Tumor debulking, chemotherapy, external radiotherapy, and radioactive iodine have poor long-term results in these patients. Although most patients with DTC enjoy a relatively good prognosis, it is clear that a subset of patients eventually die from tumor recurrence or distant metastasis. The thyroid cancer cell lines used in this experimental model were derived from patients who eventually died from their thyroid cancer.
Phenylacetate has been shown to have an antiproliferative effect in prostate carcinoma (27) , melanoma (28), rhabdomyosarcoma (29) , breast cancer (30), pancreatic adenocarcinoma (31), chronic lymphocytic leukemia (32), ovarian carcinoma (33) , and medulloblastoma and astrocytoma cell lines (34) . Consistent with other studies, we also found that growth inhibition occurred at concentrations of phenylacetate (2.5-10 mmol/L) clinically achievable. Presently, the it inhibits protein prenylation and glycosylation, which might affect the synthesis of proteins involved in cell cycle control and signal transduction (35) . Indeed, phenylacetate has been shown to down-regulate Bcl-2 and up-regulate bax/ p21 apoptosis-related genes in ovarian carcinoma cells and up-regulate p21 in K-ras mutant MCF-7ras breast cancer cell lines (33, 36) . Second, phenylacetate activates the human peroxisome proliferator-activated receptors (PPAR) (37) . The PPAR belong to the superfamily of nuclear steroid receptors (such as retinoids, vitamin D, and thyroid hormone receptors), all important regulators of cell growth and differentiation in thyroid cells (38, 39) . Last, phenylacetate may lead to DNA hypomethylation (40) .
The effects of phenylacetate, as a differentiating agent, varied among the cell lines we studied. This may be attributable to the FTC cell lines being too dedifferentiated, because they have no detectable TSH receptor, exhibit a biphasic growth response to TSH, and secrete a minimal amount of thyroglobulin (24) . Several in vitro studies have shown that TSH is an important promoter of malignant thyroid cell growth, invasion, and angiogenesis; it also inhibits apoptosis in malignant thyroid cell lines (24, 41, 42) . The decreased TSH growth response of the thyroid cancer cell lines, with phenylacetate treatment, may be attributable to the effect of phenylacetate on intracellular regulatory protein function or synthesis by inhibiting protein prenylation and glycosylation. One of the markers of DTCs is their ability to synthesize and secrete thyroglobulin, which is clinically useful in identifying patients who have persistent or recurrent thyroid cancer (43) . Because efficient glycoprotein secretion requires N-linked glycosylation, and phenylacetate inhibits protein glycosylation, we expected phenylacetate to decrease thyroglobulin secretion in the XTC-UC1 cell line (31, 44, 45) . Furthermore, the intracellular accumulation of thyroglobulin, with phenylacetate treatment of the XTC-UC1 cell line, supports this mechanism. Although there was increased radioactive iodine uptake in two (TPC-1 and XTC-UC1) cell lines, no differences were observed in the FTC cell lines. The FTC cell lines that failed to have increased radioactive iodine uptake with phenylacetate treatment are perhaps more dedifferentiated than the TPC-1 and XTC-UC1 cell lines. Similar findings have been observed with retinoic acid in human FTC cell lines; a redifferentiation effect, with respect to radioactive iodine uptake, was observed in some, but not all, cases (10, 11, 46) . In fact, Schmutzler et al. (46) have reported that the FTC cell lines (FTC-133, FTC-236, and FTC-238) did not have 125 I uptake in their experimental model but yet reported that these cells express the Na ϩ /I Ϫ symporter. These apparent differences in results could also be caused by subtle differences in experimental methods. In addition to the reproducible result with our model, we conducted 125 Iuptake assays in primary thyroid tissue culture cells and with TSH stimulation to further confirm the accuracy of our experimental model. As would be expected, we found a threeto six-times higher 125 I uptake in normal thyroid cells and an increase in 125 I uptake (60% in the XTC-UC1 cell line) after TSH stimulation. This further validates our system for measuring 125 I uptake, which is similar to that of van Herle et al. (10) who also reported 125 I uptake in FTC cell lines. Because phenylacetate activates the PPAR, up-regulates the retinoic acid receptor ␤, and has a synergistic effect with retinoic acid in inducing redifferentiation of neuroblastoma cells, the redifferentiation effect of phenylacetate (with respect to 125 I uptake) may therefore act through a mechanism similar to that of retinoic acid (37, 47) .
VEGF is a glycoprotein shown to be dependent on Nlinked glycosylation for efficient cellular secretion (48) . VEGF promotes tumor angiogenesis and growth and is overexpressed in thyroid cancers (49) . We did find phenylacetate to inhibit VEGF secretion with intracellular accumulation in some of the cell lines, which has not been previously identified. This suggests a possible antiangiogenic effect mediated by the inefficient secretion of VEGF. Adams et al. (25) have shown decreased angiogenesis in phenylacetate-treated breast cancer (MCF-7ras) xenograft, compared with unexposed tumors, and this might have been attributable to lower VEGF secretion. Taken together, they suggest that the inhibition of VEGF secretion by phenylacetate may be an important aspect of the in vivo antiproliferative effect of phenylacetate.
We have shown that phenylacetate can inhibit the growth of human thyroid cancer cell lines with an early cell cycle arrest in the G 0 -1 phase and late morphologic changes. Phenylacetate may inhibit tumor angiogenesis by inhibiting VEGF secretion. Because radioiodine uptake may be increased with phenylacetate treatment, it may be useful in patients who have tumors that take up little or no radioiodine. Given that serum phenylacetate concentrations have been safely achieved in humans, it may be beneficial in patients with DTC who fail conventional therapy or as an adjuvant treatment. Its interaction with retinoic acid is also of interest.
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